XHKG
1696
Market cap142mUSD
Jul 09, Last price
2.39HKD
1D
3.02%
1Q
-26.01%
IPO
-73.15%
Name
Sisram Medical Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Sisram Medical Ltd, an investment holding company headquartered in Caesarea, Israel, since its establishment in 2013, is engaged in the creation, production, and worldwide distribution of a broad spectrum of medical solutions. The company develops and markets energy-based aesthetic devices, minimally invasive therapeutic systems, non-energy-dependent equipment, and cosmeceuticals, reaching markets across Asia Pacific, Europe, North America, Latin America, the Middle East, and Africa. Its comprehensive range of products and treatments addresses numerous conditions, such as hair removal, skin revitalization, acne and scarring, body and facial sculpting, pigment and skin surface refinement, fat transfer procedures, injectable dermal fillers, skin tissue regeneration injectables, personal wellness items, cosmetic dental procedures, transdermal delivery methods, cellulite reduction, stretch mark amelioration, therapy for vascular and pigmented lesions, hydradermabrasion, non-surgical eyelid lifts (blepharoplasty), liposuction, as well as feminine health and sexual well-being applications. Furthermore, the company is involved in the manufacturing, distribution, and sales of general medical apparatus. Sisram Medical's offerings are available under its prominent brand names, which include Alma, Soprano, Harmony, Copulla, Foshion, Accent, and LMNT.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||